|Videos|May 3, 2021
Considerations for Selecting Therapy in RRMM
Author(s)Sagar Lonial, MD, FACP, FASCO
Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.
Advertisement
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5